Arts and Culture
More from Google
Add by RSS Feed
Get the Android app
Get the iOS app
New Retina Radio by Eyetube
New Retina Radio is a place to hear stories about retina that are told nowhere else.
2 days ago
Clinical Impacts From AAO 2020: Drs. Singh, Ehlers, and Gillies
Will data shared at AAO 2020 affect your clinical decision-making with wet AMD patients? Rishi Singh, MD, invites Justis Ehlers, MD, and Mark Gillies, MD, PhD, to review their presentations from AAO 2020 and discuss how clinical practice may be affected by their new information. Dr. Ehlers presented data on fluid volatility and the software used to measure it, and Dr. Gillies examined a 10-year data set of real-world wet AMD patients.
6 days ago
Fluid in Novascular Age-Related Macular Degeneration – Evolution of Understanding
Join Dr. Rishi Singh (USA) as he speaks with Prof. Jennifer Arnold (Australia), Prof. Mark Gillies (Australia) and Dr. SriniVas Sadda (USA) about the role and importance of fluid in the management of retinal diseases. In this episode, we will look at the different fluid compartments and our current understanding of their relevance to neovascular AMD. We will discuss the learnings gained from the HARBOR and FLUID clinical trials and the Fight Retinal Blindness! project, and consider key questions such as whether fluid can be protective and which types of fluid need to be treated aggressively.
Jan 8, 2021
[New Retina Radio Journal Club] Imaging Modalities in DR
Host Jorge Fortun, MD, and guests Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, review real-world data that compare widefield swept-source OCT angiography with ultra-widefield color fundus photography and fluorescein angiography for the detection disease activity in patients with diabetic retinopathy.
Dec 21, 2020
[New Retina Radio Journal Club] Intravitreal Dexamethasone Implant in DME Patients
Host Jorge Fortun, MD, and guests Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, discuss a retrospective study on the efficacy and safety of an intravitreal dexamethasone implant (Ozurdex, Allergan) in patients with diabetic macular edema. They review the top-line data and study design of this real-world report.
Dec 17, 2020
Clinical Impacts From AAO 2020: Drs. Singh, Do, and Heier
How will data shared at AAO 2020 impact clinical decision-making in wet AMD therapy? Rishi Singh, MD, is joined by Diana Do, MD, and Jeffrey Heier, MD, to review their talks from the AAO 2020 meeting and to see how their data might influence the day-to-day work of clinicians in retina. Dr. Do presented a meta-analysis comparing all anti-VEGF agents and regimens for the treatment of wet AMD, and Dr. Heier examined baseline patient characteristics in HAWK/HARRIER to have a better understanding of IOI events.
Dec 7, 2020
DRCR Retina Network Protocol AB at AAO
DRCR Retina Network Protocol AB compared aflibercept (Eylea, Regeneron) to PPV and PRP in patients with diabetic vitreous hemorrhage. DRCR Retina Network Vice Chair and Protocol AB chair Andrew Antoszyk, MD, joins NRR to review the study’s findings, which were presented at this year’s AAO Annual Meeting.
Dec 2, 2020
AAO Late Breaker: IRIS Registry Data on GA
Tracking real-world data on geographic atrophy has been patchwork process—until now. Thanks to the AAO IRIS Registry, real-world information on eye diseases can be gathered and assessed. What was found in the IRIS Registry regarding GA, and how will it change the way you practice? Ehsan Rahimy, MD, outlines how he and his team identified patients and trends, and summarizes how he applied the group’s findings to his practice. Dr. Rahimy presented data from this discussion during this year’s AAO Annual Meeting Late Breakers session.
Nov 30, 2020
Coding Changes for 2021 at AAO
In 2021, E/M codes will undergo their most significant changes since 1997. How will these changes affect your billing and coding—and what processes can you put in place to get ahead of the game? AAO Coding and Practice Management Executive Joy Woodke informs us of the changes ahead, which were shared at this year’s AAO Annual Meeting.
Nov 25, 2020
AAO Late Breaker: Ang-2 Mediation in DME Therapy
The next generation of therapy for DME patients will require looking beyond the VEGF pathway. In the phase 2 BOULEVARD study, researchers are assessing the safety and efficacy of the angiopoietin-2 mediator faricimab (Roche/Genentech) for the treatment of DME. Could the angiopoietin pathway present a new option for patients? Karl Csaky, MD, PhD, sits down with NRR to review data from the study, which were shared at this year’s AAO Annual Meeting Late Breakers session.
Nov 23, 2020
Retinal Arteriolar Macroaneurysm and Anti-VEGF Therapy at AAO
Retinal arteriolar macroaneurysm (RAM) usually regresses spontaneously, but can lead to irreversible vision loss if regression does not occur. Could anti-VEGF therapy be an option for these patients? J. Fernando Arevalo, MD, PhD, joins NRR to discuss data from a study that asked that question. He presented the data at this year’s AAO Annual Meeting.
Nov 20, 2020
AAO Late Breaker: KSI-301 in DME Therapy
The burden of anti-VEGF therapy is particularly high in DME patients, many of whom are young, in the workforce, and unable to easily maintain monthly therapy. Could the antibody biopolymer conjugate KSI-301 (Kodiak Sciences) alleviate that burden while maintaining the outcomes experienced with anti-VEGF therapy? Arshad M. Khanani, MD, MA, shares the results of the phase 1B, long-term, multidose study that was presented at this year’s AAO Annual Meeting Late Breakers session.
Nov 19, 2020
The Art of Drug Choice: Wet AMD and the Latest Data [Miniseries]
Arshad M. Khanani, MD, MA, leads a roundtable consisting of Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA, as they discuss the art of drug choice in wet AMD therapy. The panel discusses how and why they switch therapy in challenging wet AMD cases and reviews how the COVID-19 pandemic has factored into their treatment algorithms. Also, Dr. Fuller shares the case of a wet AMD patient whose waning response to traditional therapy required intervention with an intravitreal dexamethasone implant (Ozurdex, Allergan).
Nov 19, 2020
Phase 3 Trials in Wet AMD [Miniseries: The Art of Drug Choice: Wet AMD and the Latest Data]
In episode 2 of the NRR miniseries “The Art of Drug Choice: Wet AMD and the Latest Data,” Dr. Khanani and roundtable participants Drs. Fuller, London, and Weng review the latest phase 3 efficacy data from the HAWK/HARRIER, ARCHWAY, and CEDAR/SEQUOIA studies. Also, Dr. Weng shares the case of a wet AMD patient whose response to therapy and toleration of treatment burden mandated a change in treatment. Could brolucizumab (Beovu, Novartis) be a solution?
Nov 19, 2020
Wet AMD Pipeline [Miniseries: The Art of Drug Choice: Wet AMD and the Latest Data]
This NRR miniseries “The Art of Drug Choice: Wet AMD and the Latest Data” continues as Dr. Khanani and the roundtable participants Drs. Fuller, London, and Weng review the wet AMD pipeline with a focus on anti-Ang-2 therapy (faricimab, Roche/Genentech) and gene therapy (RGX-314, RegenxBio and ADVM-022, Adverum Biotechnologies). After the break, Dr. London shares the case of a patient with wet AMD who experienced a ceiling of response to anti-VEGF therapy. Did a switch to brolucizumab (Beovu, Novartis) result a change?
Nov 19, 2020
Safety in Wet AMD [Miniseries: The Art of Drug Choice: Wet AMD and the Latest Data]
NRR’s miniseries “The Art of Drug Choice: Wet AMD and the Latest Data” wraps up with moderator Dr. Khanani and panelists Drs. Fuller, London, and Weng discussing safety data. How have safety considerations changed in the wet AMD treatment landscape, and how do clinicians balance the risks and rewards of switching to a new agent? Additionally, Dr. Khanani closes out the series with the case of a patient whose disease stopped responding after a decade of anti-VEGF therapy. Listen here to learn how he approached the case.
Nov 18, 2020
ARCHWAY at AAO
The Port Delivery System With Ranibizumab (Genentech) is under investigation for the treatment of wet AMD in the phase 3 ARCHWAY trial, data from which was shared at this year’s AAO Annual Meeting. Nancy Holekamp, MD, sits down with NRR to provide a primary analysis of the results of ARCHWAY and discusses safety outcomes.
Nov 10, 2020
[New Retina Radio Journal Club] Putting the Fun Back in Journal Club
New Retina Radio’s John Kitchens, MD, and Jorge Fortun, MD, introduce the premier episode of New Retina Radio Journal Club, a new series dedicated to reviewing the latest papers and how they relate to day to day clinical practice. In this episode, Dr. Fortun is joined by Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, to discuss two papers that address the role, or lack thereof, of anti-VEGF therapy in the treatment of neovascular age-related macular degeneration and geographic atrophy.
Oct 30, 2020
Clinical considerations for optimal management of patients with IRDs
In this podcast, Prof. Bart Leroy (Belgium), Prof. Isabelle Audo (France) and Prof. Robert Maclaren (UK) discuss the management of patients with inherited retinal diseases (IRDs), from the initial identification of a patient with an IRD and referral to specialist center, through to the confirmation of a diagnosis using genotyping and the long-term implications for the patient of receiving that diagnosis. They discuss the current treatment landscape for patients with IRDs and outline future potential therapies on the horizon.
Oct 16, 2020
[Back to Practice] Combating Patient Misinformation Regarding COVID-19
Arming patients with knowledge is key to fighting any disease. What happens when a confluence of factors create a breeding ground for an uneducated patient population? John W. Kitchens, MD (United States), is joined by Patricio Schlottmann, MD (Argentina), Nicole Eter, MD (Germany), and Adnan Tufail, MBBS, MD, FRCOphth (United Kingdom) to review tactics for educating patients and battling misinformation in the COVID-19 era.
Oct 14, 2020
[Back to Practice] Telemedicine & Combating Patient Misinformation
The COVID-19 pandemic accelerated the use of telemedicine. How has this held up in retina now that we’ve had more than 6 months of experience under our belts? New Retina Radio host John Kitchens, MD, invites Judy E. Kim, MD; Byron Ladd, MD; and Carl D. Regillo, MD, to review how their practices have used (or not used) telemedicine during the pandemic. Also, Dr. Kitchens asks the panel how they’ve handled educating patients about the pandemic—and how they’ve tackled questions of misinformation.
Oct 3, 2020
[Back to Practice] Telemedicine in the COVID-19 Era
Telemedicine has been put to the test during the COVID-19 pandemic. How is it holding up—and just how effective will it be going forward? John W. Kitchens, MD (United States), is joined by Francesco Boscia, MD (Italy); David Steel, MBBS, FRCOphth (United Kingdom); and Ramin Tadayoni, MD, PhD (France), to discuss how much telemedicine has delivered as promised.
Oct 1, 2020
[Back to Practice] Academic Settings in a Pandemic: Rules and Regulations
The internal regulations governing academic institutions were tested during the COVID-19 surges of spring and summer. As we move into autumn, how effective have they been—and are any worth revisiting? New Retina Radio host John Kitchens, MD, reviews this topic with Dilraj Grewal, MD, from the Duke Eye Center; Adrienne Scott, MD, from the Wilmer Eye Institute; and Elliott Sohn, MD, from University of Iowa to gain a better understanding of how institutional safeguards kept patients and staff safe, and how they may have served as (sometimes necessary) roadblocks to getting practice back to pre-pandemic levels.
Sep 16, 2020
[Back to Practice] Educating the Next Generation of Surgeons During COVID-19
The disruptions to clinical and surgical workflows during the COVID-19 crisis are obvious. Less apparent are the downstream effects of adjustments to educational experiences. New Retina Radio host John Kitchens, MD, invites three leaders in academic retina—Sophie Bakri, MD, of the Mayo Clinic; Julia Haller, MD, of Wills Eye Hospital; and R.V. Paul Chan, MD, MSc, MBA, of the University of Illinois at Chicago—to discuss how training and selection of fellows has been altered during the COVID-19 pandemic, and to review the tactics their institutions have employed to mitigate the interference their programs have endured.
Aug 30, 2020
jCell Therapy for Retinitis Pigmentosa and Phase 2B Data
Approaches to treating retinitis pigmentosa have included prosthetic devices and gene therapy. What if there was an approach that could treat the nearly 2 million worldwide patients with disease? Anthony Joseph, MD, discusses jCell technology, which may work independently of a patient’s genetic subtype to promote photoreceptor survival in retinitis pigmentosa patients. What data from a phase 2b trial were used to evaluate the efficacy of jCell technology? How will the therapy be tested going forward? What safety concerns should clinicians be aware of? Dr. Joseph has some answers.
Aug 28, 2020
[Back to Practice] What Happens During a COVID-19 Resurgence?
A COVID-19 resurgence seems increasingly likely as autumn and winter approach the United States, forcing people indoors and increasing transmission risk. What can retina clinicians learn from the spring and summers waves of COVID-19 infections that could be applied to the cooler months of 2020? John W. Kitchens, MD, invites Steve Charles, MD; Amy Schefler, MD; and Jayanth Sridhar, MD, to gameplan the future of retina clinics.
Aug 26, 2020
[Back to Practice] Technology and COVID-19: Necessity Is the Mother of Invention
Retina’s ability to adjust to a new environment should be commended. Which of the technologies introduced during the COVID-19 era are stopgaps and which will be a permanent part of the treatment landscape? John W. Kitchens, MD (United States), is joined by María H. Berrocal, MD (United States); Jean-Francois Korobelnik, MD, PhD (France); and Manish Nagpal, MBBS, MS, FRCS (Edin) (India), to forecast the future of retina’s technologic milieu.
Aug 21, 2020
Treat-and-Extend in the Real World
Treat-and-extend therapy is a common tactic employed by retina specialists for treating wet AMD patients. What new data will grow the body of information retina specialists already draw on when making decisions about treatment regimen? Michael Singer, MD, shares details from a retrospective review of patient data over a 2-year period during which treat-and-extend regimens were employed.
Aug 12, 2020
Opioid Prescribing Patterns Among Retina Specialists
In the midst of the COVID-19 pandemic, medicine cannot forget about the raging opioid epidemic taking place in the United States. What role to retina specialists play in fueling the opioid crisis, and how has their behavior changed for the better over time? Yoshihiro Yonekawa, MD, shares his research about opioid prescribing rates among retina specialists, tracing the field’s behavior over time, and offering a window into the specialty’s role in the crisis.
Aug 4, 2020
Continuous Dosing in LADDER
The phase 2 LADDER study showed the Port Delivery System for ranibizumab was worthy of a phase 3 trial. Was the device able to deliver a continuous dose of therapy that was similar to what you’d find in monthly injection patients? Dilsher Dhoot, MD, reviews the pharmacokinetic data that researchers used to determine the rate of drug release and therapeutic benefit and previews the phase 3 ARCHWAY trial.
Aug 3, 2020
[Back to Practice] COVID-19 Clinical and Surgical Protocols: Which Changes Are Here to Stay?
Protocols for clinical and surgical settings have been altered in the COVID-19 era. Which of those protocols are temporary, and which protocols will be a permanent part of practice? To answer this question, New Retina Radio host John W. Kitchens, MD, invites María Ana Castellanos-Martinez, MD (Mexico) and Matteo Forlini, MD (Italy) for a roundtable discussion on the future of retina care in the wake of COVID-19–related changes.
Jul 30, 2020
[Back to Practice] Education as In-Person Meetings Are Paused
Conferences are an essential dynamic to the retina ecosystem that have been disrupted during the COVID-19 crisis. How will the field advance without in-person meetings? New Retina Radio host John W. Kitchens, MD, invites EURETINA General Secretary Anat Loewenstein, MD, and ASRS President Timothy G. Murray, MD, MBA, to discuss the future of in-person education, the evolving dynamics of physician-industry collaboration, and the solutions that retina societies have relied on to maintain retina’s camaraderie.
Jun 30, 2020
Faricimab in Phase 2 and 3
Safe and effective long-duration therapy in wet AMD treatment could be the solution to increasing patient adherence. Are we on the brink of a major breakthrough? Carl Danzig, MD, reviews the phase 2 STAIRWAY study, which evaluated the safety and efficacy of faricimab (Genentech/Roche) for the treatment of wet AMD, and previews the coming phase 3 trials TENAYA and LUCERNE.
Jun 22, 2020
Surgical Implantation of RPE Cells Derived From Human Embryonic Stem Cells
Dry AMD research was a hot topic at this year's ARVO annual meeting. Could ethically sourced stem cells from human embryos provide a solution to this challenging disease? Chris Riemann, MD, shared data from an early phase trial that sought to understand the safety of RPE cells surgically implanted below the retina.
Jun 15, 2020
From an In-person Convention to a Virtual Event: Updates From ARVO 2020
The ARVO Board of Trustees had only a few weeks to turn their massive, in-person meeting into a virtual symposium that highlighted the year's biggest advancements in ophthalmology research. Iris Rush, the Executive Director of ARVO, spoke to New Retina Radio about the experience, and spelled out what they learned that can be applied to future ARVO meetings.
May 29, 2020
PANORAMA 100-Week Data: Updates From ARVO 2020
In-person retina conferences are halted, but the flow of data isn't. In this episode of New Retina Radio, Jennifer Lim, MD, breaks down 100-week data from the PANORAMA trial, which she shared at the ARVO virtual meeting. Dr. Lim's presentation may help retina doctors make informed treatment decisions about long-term therapy for nonproliferative diabetic retinopathy.
May 22, 2020
COVID-19: International Perspectives
National responses to the COVID-19 pandemic have varied. Will responses in the retina clinic look more homogenous than governments' actions have? NRR Guest Host María Berrocal, MD (United States), invites Hai Lu, MD (China), Virgilio Morales-Canton, MD (Mexico), and Martin Charles, MD (Argentina), to discuss how the global retina community will communicate, act, and respond in the months ahead.
May 20, 2020
COVID-19: Are Today's Protocols Tomorrow's Routines?
Protocols have changed significantly during the COVID-19 pandemic. Which of those procedures are here to stay and which will disappear as the pandemic subsides? NRR host John Kitchens, MD, invites Murtaza "Moo" Adam, MD; David R.P. Almeida, MD, PhD, MBA; and Christina Weng, MD, MBA, to discuss which changes implemented in 2020 will be permanent fixtures in retina practice.
May 18, 2020
COVID-19: Views From Egypt, Italy, Sweden, and the United States
New Retina Radio checks in with different corners of the globe to hear how retina specialists are responding to changing conditions in their nations. NRR host Allen Ho, MD (United States), and guest host Ehab El-Rayes, MD, PhD (Egypt), invite Matteo Forlini, MD (Italy), and Monica Lövestam-Adrian, MD (Sweden), to share their tactics for providing optimal patient care in the wake of a global pandemic.
May 13, 2020
COVID-19: Key Technologies
The COVID-19 crisis has forced retina specialists to implement a number of protocols-and wish for a number of technologies. Which of those will endure after the pandemic subsides and which are particular to the moment? NRR host John Kitchens, MD, is joined by Caroline Baumal, MD; María Berrocal, MD; and Judy Kim, MD, to discuss which practices will be rolled into modern protocols, which technologies on the horizon may have greater value in a post-COVID world, and how treatment decisions have (or have not) been adjusted to face today's unique challenges.
1 hr 1 min
May 8, 2020
COVID-19: A Global Response
As the COVID-19 pandemic rages in some places and subsides in others, retina-focused societies from around the world must provide guidance to their members. How are different organizations doing so? Special guest host and president of the Retina World Congress Tarek Hassan, MD (United States), sits down with Asia-Pacific VitreoRetina Society leadership member Paisan Ruamviboonsuk, MD (Thailand), and Pan-American Association of Ophthalmology Immediate Past-President J. Fernando Arevalo, MD, PhD (United States), and Euretina General Secretary Anat Loewenstein, MD (Israel).
May 6, 2020
COVID-19: Telemedicine in Retina
Telemedicine in retina has been pregnant with promise. Is it time to deliver? NRR host John Kitchens, MD, dives into this conversation with S.K. Steven Houston III, MD; John B. Miller, MD; and Ehsan Rahimy, MD, to understand telemedicine's viability and durability during and beyond the COVID-19 era, and to review proper coding tactics to ensure compliance.
1 hr 17 min
May 1, 2020
COVID-19: Evolving Conditions in Asia
The COVID-19 outbreak started months ago in Wuhan, China, but many parts of Asia are feeling the brunt of the pandemic now. How are retina specialists in various regions handling it? New Retina Radio hosts Allen C. Ho, MD, and R.V. Paul Chan, MD, MBA, check in with retina specialists Shunji Kusaka, MD, PhD (Japan); Manish Nagpal, MS, DO, FRCS(UK) (India); and Wei-Chi Wu, MD, PhD (Taiwan).
Apr 29, 2020
COVID-19: Can Clinical Trials Proceed?
Can clinical trials go forward during the COVID-19 crisis? If so, how? And if not, then how do we proceed? NRR host John Kitchens, MD, and special co-moderator Namrata Saroj, OD, invite clinical trial veterans Jeffrey Heier, MD; Carl Regillo, MD; and Charles Wykoff, MD, PhD, to discuss the future of one of retina's most important components.
Apr 24, 2020
COVID-19 Updates From Europe
How will the COVID-19 crisis transform retina care in Europe? New Retina Radio asks these questions with Jordi Monés, MD, PhD (Spain), at the helm. He is joined by David H.W. Steel, MBBS, FRCOphth (United Kingdom); Murat Oncel, MD (Turkey); and Armin Wolf, MD, FEBO (Germany), to hear about the future of retina care in the wake of COVID-19.
1 hr 1 min
Apr 22, 2020
COVID-19: Fellowship and Training in Flux
Retina fellowships are one of the crown jewels of ophthalmology. But what happens to trainees during the COVID-19 crisis? NRR host John Kitchens, MD, is joined by attendings Sharon Fekrat, MD, from the Duke Eye Center; Thomas Albini, MD, from the Bascom Palmer Eye Institute; and Prithvi Mruthyunjaya, MD, MHS, from the Byers Eye Institute at Stanford University, to hash out the new realities of retina fellowship training.
1 hr 2 min
Apr 17, 2020
COVID-19 Crisis in Latin America
New Retina Radio's global series continues as we check in on Latin America. Allen C. Ho, MD, and María H. Berrocal, MD, invite Lihteh Wu, MD (Costa Rica); Gustavo Hüning, MD, MBA (Brazil); and Maria Ana Martinez Castellanos, MD, to share their experiences with COVID-19.
Apr 17, 2020
COVID-19 Crisis: The Role of AAO and ASRS
What role do professional organizations play in the COVID-19 crisis? NRR host John Kitchens, MD, invites AAO CEO David W. Parke II, MD, and AAO Immediate Past President George Williams, MD, to the program to discuss how the Academy is helping shepherd ophthalmologists through the current situation. Also joining Dr. Kitchens are Timothy G. Murray, MD, MBA, president of the ASRS, and J. Michael Jumper, MD, ASRS Chair of Education and the COVID-19 Task Force, who discuss how retina's largest organization is guiding its members to success.
1 hr 1 min
Apr 15, 2020
COVID-19 Crisis in Asia
R.V. Paul Chan, MD, MSc, and Allen C. Ho, MD, host a panel comprised of Seung-Young Yu, MD (South Korea); Daniel Ting, MD, PhD (Singapore); and Paisan Ruamviboonsuk, MD (Thailand). The moderators and panel will discuss the evolving situation in Asia and how various medical systems have responded to the COVID-19 crisis.
Apr 9, 2020
Business of Retina in the COVID-19 Era; What to Do With Your Practice
John W. Kitchens, MD, joins Alan Ruby, MD, and Robert Foster, MD, to discuss the business of retina in the COVID-19 era, covering everything from the merits of applying for government loans to the effects of COVID-19 on private equity trends.
1 hr 11 min
Apr 4, 2020
COVID-19 in Europe: Reports From the Ground
Allen C. Ho, MD, hears from Italian retina specialist Stanislao Rizzo, MD, Spanish retinal specialist Jordi Monés, MD, PhD, and French retinal specialist Ramin Tadayoni, MD, PhD, about the conditions in European medical centers during the COVID-19 crisis.
Apr 2, 2020
COVID-19: Reports From US Hot Zones
John Kitchens, MD, hosts George Williams, MD, from Associated Retina Consultants outside of Detroit; Gwen Cousins, MD, from Retina Associates New Orleans; and Lisa Olmos de Koo, MD, MBA, from the University of Washington in Seattle, to hear how COVID-19 outbreaks in their respective cities have changed retina practice-and the practice of medicine in general.
Mar 27, 2020
COVID-19: How COVID-19 Affects US Retina Practices
John Kitchens, MD, hosts Sunir Garg, MD; Nancy Holekamp, MD; and Rishi Singh, MD, to learn how each of their practices has been affected by the COVID-19 crisis. They discuss new patient protocols, staffing complications, and working with colleagues who are at risk for contracting COVID-19.
Mar 23, 2020
COVID-19: Trials in Transmission
Gary Wörtz, MD, and Blake Williamson, MD, MPH, discuss COVID-19 transmission with Karl Stonecipher, MD, and Julie Schallhorn, MD, MS. Drs. Stonecipher and Schallhorn share tactics for protecting staff, family members, and physicians from contracting the virus, and urge listeners to remind their friends and family that this is not a drill.
Nov 25, 2019
Uveitis and Infectious Eye Disease
The heterogeneous nature of uveitis makes it a challenging disease to treat. Phoebe Lin, MD, PhD, reviews common mistakes in uveitis management that an AAO panel found worthy of highlighting. And Steven Yeh, MD, discusses which emerging infectious diseases retina specialists need to know about-and what they can do when they encounter them.
Nov 18, 2019
Ocular Oncology at the AAO Annual Meeting
Uveal melanoma carries a risk of metastasis, which may occur before the disease is even detected. Moreover, even when uveal melanoma is treated, there's a good chance that the radiation used during therapy will result in radiation retinopathy. Prithvi Mruthyunjaya, MD, MHS, reviews the state of uveal melanoma therapies in clinical trials and discusses how doctors might employ new tactics to prevent metastatic disease. Also, Amy Schefler, MD, outlines a trial examining how patients with radiation retinopathy respond to anti-VEGF therapy. How could this change the visual function of patients whose cancer treatments left them visually impaired?
Nov 12, 2019
Late-Breaking Phase 3 Data From AAO Retina Subspecialty Day
Brolucizumab (Beovu, Novartis) was approved by the US FDA for the treatment of wet AMD. But how does it affect patients with polypoidal choroidal vasculopathy? Glenn Jaffe, MD, joins the podcast to discuss a substudy in the phase 3 HAWK trial that aimed to find out. Also, as the FDA reviews a new drug application for abicipar pegol (Allergan), what can we learn from the phase 3 trials CEDAR and SEQUOIA now that the 2-year data were released? Rahul Khurana, MD, details his presentation live from the BMC booth.
Nov 1, 2019
Diabetic Eye Disease: What's Next for Your Patients?
Diabetic retinopathy may be proliferative or nonproliferative, and patients may present with or without macular edema. And then there's the possibility that one patient's disease is VEGF-mediated whereas another's is not. With all of these factors, it's important to understand which therapeutic options work best for particular patients. Nathan Steinle, MD, reviews data from the BOULEVARD trial, a phase 2 study evaluating faricimab (Genentech/Roche) in patients with DME. And Rishi Singh, MD, parses the 52-week data from the PANORAMA trial, which evaluated the effect of aflibercept (Eylea, Regeneron) in approximately 400 patients with high-risk NPDR without DME.
Jun 15, 2018
Anti-VEGF, A Biography: Part 3
This story started in the early days of VEGF's isolation in the 1970s and brought us to the discovery of ranibizumab and bevacizumab in the mid 2000s. The data revealed at the ASRS meeting in 2005 would change retina forever-and usher in a new competitor with a chance to disrupt the landscape yet again. Don't miss the final episode of this fascinating and important story told by those that lived it. We're bringing back some of the voices you've heard before, and some new ones, too. John D. Pitcher III, MD, invites Bob Avery, MD; David Brown, MD; Jeffrey Heier, MD; Nancy Holekamp, MD; Kirk Packo, MD; Phillip Rosenfeld, MD, PhD; and Bob Vitti, MD, to tell the latest chapter of anti-VEGF's biography.
Nov 22, 2017
Anti-VEGF, A Biography: Part 2
New Retina Radio continues its biography of anti-VEGF. John D. Pitcher III, MD, picks up the story where we left off: in a world where pegaptanib was the only intravitreal injection approved for treating wet AMD. But a deep dive into the literature and a few calculations on the back of a napkin are about to change retina practice forever. Guests in this episode include Bob Avery, MD; Dave Brown, MD; Anne Fung, MD; Jeffrey Heier, MD; Andrew Moshfeghi, MD, MBA; Kirk Packo, MD; and Philip Rosenfeld, MD, PhD.
Aug 28, 2017
Beyond the Walls of ORs and Borders of Nations
Practicing retina in the developing world means facing frustrating, unexpected, and sometimes dangerous circumstances. Don D'Amico, MD, R.V. Paul Chan, MD, and Pravin Dugel, MD, share their stories of engaging medical communities from Tanzania to Armenia and Vietnam to Nepal.
Jun 13, 2017
Retina Is for the Birds
Hawks have more than one fovea and a cornea that changes shape to sharpen focus on prey. Who knew? Well, one retina doctor did. James C. Major Jr, MD, PhD, joins us for an episode to review his early contributions to animal imaging. But the story is bigger than that. Dr. Major's journey illustrates that a marriage between two passions-in his case, the blossoming world of optical coherence tomography in the early 2000s and an ornithological hobby-can send a retina doctor down uncharted paths of scientific discovery.
Apr 24, 2017
Anti-VEGF, A Biography: Part 1
Many young retina specialists have always known retina as an anti-VEGF world. But how did this happen? John D. Pitcher III, MD, joins Scott and Ranna in studio to deliver the first part of the tale of anti-VEGF in retina, taking the story back to the 1970s to tell the story of the discovery of VEGF, the creation of pegaptanib, and the struggles that early anti-VEGF encountered in retina. There are a lot of guests for this one, but the major players for this episode are Tony Adamis, MD; Bob Avery, MD; Jeff Heier, MD; and Kirk Packo, MD.
Feb 24, 2017
Alphabet Soup: PhD, MBA, JD, MS
All retina specialists have an MD; not all retina specialists have another postgraduate degree. In this episode of New Retina Radio, we examine how and why those degrees were obtained by retina specialists-and if they were even worth the time. Featuring Derek Kunimoto, MD, JD; Paul Hahn, MD, PhD; David Almeida, MD, PhD, MBA; and Scott Walter, MD, MS.
Jan 23, 2017
The Dating Game
Finding a partner for your retina practice can be a lot like dating-you need to find someone whose values align with your values, who enhances your best qualities, and who doesn't make you pull your hair out. In this episode, New Retina Radio goes retro-think The Dating Game but (slightly) less corny. Featuring Geeta Lalwani, MD, and Charlie Mango, MD.
Dec 28, 2016
Je Ne Sais Quoi
Last episode, we heard from women at various stages in their careers about the unique nature of practicing retina as a woman. In part 2 of 2, they discuss the role of men in the development of women, the merits of joining groups like Women in Retina, and how experience shapes perception of how the industry treats female candidates. Featuring Julia Haller, MD; Anat Loewenstein, MD; Geeta Lalwani, MD; Jessica Randolph, MD; and Talisa de Carlo, MD.
Nov 16, 2016
Practicing retina consumes your life. Add a pair of X chromosomes into the mix, and you face a very different set of circumstances. In the debut episode of New Retina Radio, we sit down with Julia Haller, MD; Anat Loewenstein, MD; Jessica Randolph, MD; and Talisa de Carlo, MD, to hear about the how women in retina operate-and how men factor into the equation.